Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

The world’s first automated laximetry device that replicates daily movements and activities through a dynamic test.

Descripción del proyecto

Un dispositivo innovador para la medición automatizada de la laximetría dinámica

El ligamento cruzado anterior (LCA) es un componente fundamental de la rodilla. El tratamiento de referencia actual para diagnosticar lesiones en el LCA es la prueba de Lachman, que mide la «laxitud» (soltura) de los ligamentos de la rodilla. Este proceso es fiable cuando lo lleva a cabo un especialista. Sin embargo, los médicos de cabecera y no especialistas necesitan un examen con rayos X o resonancia magnética nuclear (RMN) para confirmar el diagnóstico. El equipo del proyecto financiado con fondos europeos Dyneelax propone el primer dispositivo médico para la medición automatizada de la laximetría dinámica independientemente de reconocimientos como pruebas con rayos X y RMN. El dispositivo lleva a cabo pruebas de Lachman y exámenes de la estabilidad rotacional objetivos y reproducibles para determinar la laximetría del LCA y realizar diagnóstico y el pronóstico del estado de recuperación.

Objetivo

The knee is the largest, and one of the most complex and fragile joints in the human body, and the anterior cruciate ligament (ACL) is one of its core components. The ACL is vital to healthy knee function, stabilising the joint throughout its range of motion.
In order to diagnose ACL injuries, the current gold standard is the Lachman’s test, which measures the ‘laxity’ (looseness) of the ligaments in the knee. Often done by hand, this is a reliable process when carried out by a specialist such as an orthopaedist. In contrast, general practitioners (GPs) and other non-specialists require x-ray or magnetic resonance imaging (MRI) exams to confirm their diagnosis. However, waiting periods for mechanised tests in the EU are long, sometimes entirely unpredictable, due to limited equipment availability and the need to prioritise emergency cases.

To overcome this, Genourob has developed Dyneelax, which is the first medical device for automated dynamic laximetry measurement. Dyneelax carries out objective and reproducible Lachman’s tests and rotational exams to assess the laximetry of the ACL. Automation and standardisation of this non-invasive, quantitative testing allows the diagnosis and prognosis of ACL injury and recovery status. It is independent of examinations such as x-ray and MRI scans and it can be used also by non-specialists such as GPs. This means quicker, more effective treatment for better recovery of patients.

At Genourob our mission is to transform the clinical protocol for diagnosing and prognosis of ACL injuries. In this way, GPs would be patients’ main point of contact with the healthcare system, replacing the need to wait for an MRI scan or x-ray for ACL injuries’ treatment. The SME Instrument grant is ideal for completing our product roadmap as it will enable our post-market surveillance to be carried out, to allow us to make the clinical claim that Dyneelax is an effective substitute for MRI scans in diagnosing and evaluating injuries to the ACL

Convocatoria de propuestas

H2020-EIC-SMEInst-2018-2020

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SMEInst-2018-2020-1

Régimen de financiación

SME-1 - SME instrument phase 1

Coordinador

GENOUROB
Aportación neta de la UEn
€ 50 000,00
Dirección
BAT 60 RUE HENRI GERET
53000 LAVAL
Francia

Ver en el mapa

Pyme

Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.

Región
Pays de la Loire Pays de la Loire Mayenne
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 71 429,00